

S94 - KOS DIAGNOSTIC LAB 6349/1, NICLOSON ROAD, AMBALA CANTT, Ambala

Lab No. : 146023758 Age: 77 Years Gender: Male Reported : 8/2/2021 9:29:23AM

A/c Status : P Ref By : Dr. KOS DIAGNOSTIC LAB Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
DES-GAMMA CARBOXY PROTHROMBIN	46	mAU/mL	<40
(DCP)/PIVKA II, SERU @			
(CMIA)			

#### Note:

- 1. Patient samples may contain heterophilic antibodies or mouse monoclonal antibodies that could react in immunoassays to give a falsely elevated or depressed result.
- 2. Results should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.
- 3. False low values may be observed in patients receiving vitamin K analogues.
- 4. False high values may be observed in patients receiving vitamin K antagonists, antimicrobial drugs, with diet low in vitamin K or in patients with ongoing alcohol intake.

## Comment:

Des-gamma carboxyprothrombin (DCP) also known as PIVKA II (Prothrombin induced by Vitamin K antagonist II) is an abnormal prothrombin that is increased in the sera of patients with Hepatocellular Carcinoma (HCC). Unlike AFP, it is not elevated in Chronic Liver Disease, Cirrhosis, pregnancy or Germ Cell Tumors. It is a complementary biomarker to AFP in HCC and increases the sensitivity (83%) and specificity (84%) for HCC when used in combination.

It is recommended to measure two or more different tumor markers (AFP, DCP or AFP L3) for the diagnosis of HCC at an early stage.1,2

DCP has also been found to correlate better with tumor size, histological grade, portal vein invasion and/or intrahepatic metastasis in patients with HCC.

# Usage:

- 1. Risk assessment of patients with Chronic Liver Disease for development of HCC
- 2. To aid in the diagnosis and prognosis of patients with HCC
- 3. To monitor therapeutic efficacy in patients with HCC

# References:

- 1. Development of Evidence Based Clinical Guidelines for the diagnosis and treatment of Hepatocellular Carcinoma in Japan. *Hepatology Research 2008; 38: 37 51*
- 2. Prevention of Hepatocellular Carcinoma in the Asia Pacific Region: Consensus Statements. *Journal of Gastroenterology and Hepatology* **25** (2010) 657-663



Page 1 of 2



S94 - KOS DIAGNOSTIC LAB 6349/1, NICLOSON ROAD, AMBALA CANTT, Ambala

Name : Mr. S.K AGNIHOTRI

146023758

Collected : 4/2/2021 2:10:00PM

Received : 4/2/2021 2:42:14PM
Reported : 8/2/2021 9:29:23AM

A/c Status : P Ref By : Dr. KOS DIAGNOSTIC LAB Report Status : Final

Gender:

Test Name Results Units Bio. Ref. Interval

Male

Thangeher

NRL - Dr Lal PathLabs Ltd

Lab No.

Dr Himangshu Mazumdar MD, Biochemistry Senior Consultant - Clinical Chemistry & Biochemical Genetics Dr.Kamal Modi MD, Biochemistry Consultant Biochemist NRL - Dr Lal PathLabs Ltd

Age: 77 Years

Dr Nimmi Kansal MD, Biochemistry National Head - Clinical Chemistry & Biochemical Genetics

NRL - Dr Lal PathLabs Ltd

-----End of report -----

### **IMPORTANT INSTRUCTIONS**

\*Test results released pertain to the specimen submitted.\*All test results are dependent on the quality of the sample received by the Laboratory.

\*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician.\*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.\*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.\*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.\*Test results may show interlaboratory variations.\*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).\*Test results are not valid for medico legal purposes. \*Contact customer care Tel No. +91-11-39885050 for all queries related to test results.

(#) Sample drawn from outside source.